Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ART12.11** is Artelo Biosciences' proprietary oral crystalline cocrystal composition of cannabidiol and tetramethylpyrazine. The candidate is designed to improve cannabidiol solubility, stability, and systemic exposure relative to conventional cannabidiol formulations. In rodent chronic-stress models, oral ART12.11 produced antidepressant-like and anxiolytic-like effects that exceeded cannabidiol alone, tetramethylpyrazine alone, and a noncrystalline cannabidiol plus tetramethylpyrazine mixture. It is being developed for depressive and anxiety disorders, with human studies planned but not confirmed as initiated in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ART12.11.